Nitin Jain: Looking forward to frontline Rx for patients with CLL at EHA2024

Nitin Jain, Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Looking forward to presenting investigator initiated phase 2 trial of time-limited pirtobrutinib + venetoclax + obinutuzumab as frontline Rx for patients with CLL at European Hematology Association 2024.”

Read further.
Source: Nitin Jain/X